UPCDC-30245
UPCDC-30245 is an allosteric p97 inhibitor with an IC50 of approximately 27 nM[1]. UPCDC-30245 inhibits the p97 mutant N660K similar to wild type (WT; IC50=300 nM) and shows 3-fold resistance for p97 mutant T688A[2]. UPCDC-30245 can be used in the research of cancer[1][2][3].
Product Specifications
CAS Number
1883351-01-6
UNSPSC
12352005
Hazard Statement
H315, H319, H335
Target
P97
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/upcdc-30245.html
Purity
99.85
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
CC(N1CCN(CCNC2CCN(C3=CC=CC(C(N4)=CC5=C4C=CC(F)=C5)=C3)CC2)CC1)C
Molecular Formula
C28H38FN5
Molecular Weight
463.63
Precautions
H315, H319, H335
References & Citations
[1]Banerjee S, et al. 2.3 Å resolution cryo-EM structure of human p97 and mechanism of allosteric inhibition. Science. 2016 Feb 19;351 (6275) :871-5.|[2]Wang F, et al. Allosteric p97 Inhibitors Can Overcome Resistance to ATP-Competitive p97 Inhibitors for Potential Anticancer Therapy. ChemMedChem. 2020 Apr 20;15 (8) :685-694.|[3]Wang F, et al. Temporal proteomics reveal specific cell cycle oncoprotein downregulation by p97/VCP inhibition. Cell Chem Biol. 2021 Nov 23:S2451-9456 (21) 00482-7.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
